Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.

@article{Lanata2012ImmunogenicityAS,
  title={Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.},
  author={Claudio Franco Lanata and Teresa Raquel de Moraes Andrade and Ana Isabel Gil and Cynthia Terrones and Omar Valladolid and Betzana Zambrano and Melanie Saville and Denis Crevat},
  journal={Vaccine},
  year={2012},
  volume={30 41},
  pages={5935-41}
}
In a randomized, placebo-controlled, monocenter, observer blinded study conducted in an area where dengue is endemic, we assessed the safety and immunogenicity of a recombinant, live, attenuated, tetravalent dengue vaccine candidate (CYD-TDV) in 2-11 year-olds with varying levels of pre-existing yellow-fever immunity due to vaccination 1-7 years previously. 199 children received 3 injections of CYD-TDV (months 0, 6 and 12) and 99 received placebo (months 0 and 6) or pneumococcal polysaccharide… CONTINUE READING
22 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Trends Nicaragua

  • A Balmaseda, K Standish, JC Mercado, JC Matute, Y Tellez, S Saborio
  • Am J Trop Med Hyg
  • 2011

in children , adolescents and adults in a dengue endemic country : randomized controlled phase I trial in the Philippines

  • JL Poo, JF GalánHerrera, R Forrat, B Zambrano, J Lang, G Dayan
  • 2011

Similar Papers

Loading similar papers…